Condition
Endometrial Carcinoma Stage III
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Early P 1 (2)
Trial Status
Enrolling By Invitation1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT05691010Early Phase 1Recruiting
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT07316361Early Phase 1Enrolling By Invitation
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
Showing all 2 trials